GLP-1 Medications and Gout: What the Research Shows About Uric Acid and Weight Loss

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and does not constitute medical advice. Clinical research cited here was conducted using FDA-approved pharmaceutical compounds unless otherwise noted. Results from studies of FDA-approved medications may not apply to compounded products. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

For many people living with gout, the connection between their weight and their flares is not abstract. It is something they feel in real time. A period of weight gain, and the attacks come more frequently. A few months of improved diet, and the joints quiet down.

That observation has solid science behind it, and it is now intersecting with one of the most significant developments in obesity medicine: the rise of GLP-1 receptor agonists.

Two of the most widely studied GLP-1 medications, semaglutide and tirzepatide, reduce body weight substantially. That weight loss, the research now suggests, may carry a meaningful benefit for people with gout or elevated uric acid. Several studies published between 2024 and 2026 have directly examined what these medications do to serum urate levels, and the findings are worth understanding if you are managing both conditions.

This article walks through what gout is, why it is so closely tied to metabolic health and obesity, what the most recent research shows about GLP-1 medications and uric acid, and what to discuss with your provider if both conditions apply to you.

---

What Gout Is and Why It Is So Common Now

Gout is a form of inflammatory arthritis caused by excess uric acid in the blood, a condition called hyperuricemia. When uric acid concentrations exceed the body's capacity to keep it dissolved, it forms sharp monosodium urate crystals that deposit in joints, tendons, and surrounding tissue. The result is a gout flare: intense, sudden joint pain, typically in the big toe, ankle, or knee, that can last for days or weeks.

Gout is not rare. It affects roughly 9 million Americans, making it the most common form of inflammatory arthritis in adults. Its prevalence has roughly doubled over the past three decades, tracking closely with rising rates of obesity, metabolic syndrome, and type 2 diabetes.

That overlap is not coincidental. Hyperuricemia and gout are tightly woven into the same metabolic fabric as excess weight, insulin resistance, and chronic inflammation. A 2026 analysis published in *Frontiers in Endocrinology* found that hyperuricemia was significantly correlated with multiple components of metabolic syndrome in people with type 2 diabetes, reinforcing the picture of uric acid as a metabolic marker, not just a joint problem (PMID 41890181).

---

Why Obesity Raises Uric Acid Levels

Uric acid is produced when the body breaks down purines, compounds found naturally in food and in the body's own cellular turnover. Normally, the kidneys filter most uric acid and excrete it in urine. Several things go wrong with this system in the context of obesity and metabolic syndrome.

First, excess weight increases purine production through elevated cellular turnover and greater metabolic load. Second, and perhaps more important, insulin resistance impairs the kidneys' ability to excrete uric acid efficiently. When insulin signals poorly, urate transporters in the kidney reabsorb more uric acid than they release, driving levels higher even without major dietary changes.

This means that for many people with gout, treating uric acid without addressing the underlying metabolic dysfunction is fighting an uphill battle. Urate-lowering therapy and dietary restrictions help, but the metabolic driver keeps pushing the baseline up.

Weight loss changes that equation. Multiple studies have documented that meaningful, sustained weight reduction lowers serum urate, sometimes substantially. A 2025 longitudinal study in *Arthritis and Rheumatology* followed people across annual medical examinations and found that weight reduction was independently associated with reaching target serum urate levels, with greater weight loss corresponding to greater urate reduction (PMID 39400956). This is not a marginal finding. It suggests that weight loss is not just complementary to gout management, it is one of the most powerful levers available.

A 2025 systematic review published in *Updates in Surgery* examined the gout and hyperuricemia outcomes of bariatric surgery, a form of significant, medically induced weight loss. The review found consistent reductions in serum uric acid after surgery across multiple study populations, with some patients achieving remission of gout entirely (PMID 39520613). Bariatric surgery achieves weight loss through a different mechanism than GLP-1 therapy, but the metabolic parallels are informative: when excess weight comes off, uric acid levels tend to follow.

---

What GLP-1 Research Shows About Uric Acid

The direct question, whether GLP-1 receptor agonists lower uric acid, has now been examined in several research settings. The results are consistent.

Tirzepatide and the SURMOUNT Trials

In 2026, researchers published a post-hoc analysis of uric acid data from the SURMOUNT clinical trial program, which studied tirzepatide (the active ingredient in FDA-approved Mounjaro and Zepbound) in adults with obesity. The analysis, led by Naveed Sattar and published in *Annals of the Rheumatic Diseases*, examined how serum uric acid changed over the trial period and whether those changes were linked to weight loss (PMID 41198460).

The findings were notable. Tirzepatide produced significant reductions in uric acid levels. Importantly, the analysis found that the reduction was strongly associated with the amount of weight lost, suggesting that the uric acid benefit is mediated primarily through weight reduction rather than a direct pharmacological effect on urate transport.

This distinction matters for how to interpret the data. It means that the degree of benefit a person experiences may depend substantially on how much weight they lose, consistent with what the general weight loss literature shows.

*Tirzepatide is the active ingredient in FDA-approved Mounjaro and Zepbound, which are registered trademarks of Eli Lilly and Company. Compounded tirzepatide is not FDA-approved and is not the same as, equivalent to, or interchangeable with these products. The research above was conducted using FDA-approved tirzepatide, not compounded formulations.*

Semaglutide and Real-World Urate Data

A 2025 real-world analysis published in *Seminars in Arthritis and Rheumatism* examined what happened to serum urate levels in people with type 2 diabetes who were treated with oral semaglutide (PMID 40816061). The retrospective analysis by Moreno-Pérez and colleagues found that oral semaglutide was associated with reductions in serum urate levels, with the magnitude of reduction correlating with weight loss achieved during treatment.

This real-world data complements the controlled trial findings and suggests the relationship between GLP-1-driven weight loss and urate reduction holds outside of tightly controlled research settings.

*Semaglutide is the active ingredient in FDA-approved Ozempic, Wegovy, and Rybelsus, which are registered trademarks of Novo Nordisk A/S. Compounded semaglutide is not FDA-approved and is not equivalent to or interchangeable with these products.*

---

What Drives the Uric Acid Reduction

Based on the available research, the reduction in uric acid seen with GLP-1 medications appears to operate through several converging pathways.

Weight loss itself. As described above, reducing body weight directly lowers the metabolic drivers of hyperuricemia: less excess purine production from cellular turnover, improved insulin sensitivity that allows the kidneys to excrete urate more efficiently, and reduced dietary purine load as eating patterns shift.

Improved insulin sensitivity. GLP-1 receptor agonists reduce insulin resistance substantially, which directly benefits urate clearance through the kidneys. Better insulin signaling means urate transporters work more normally, excreting rather than reabsorbing excess uric acid.

Reduced systemic inflammation. Gout flares are triggered by inflammatory cascades. GLP-1 medications have documented anti-inflammatory effects, which may reduce flare frequency and severity through pathways beyond uric acid reduction alone.

A 2025 review published in *Journal of Clinical Medicine* examined the broad cardiovascular-kidney-metabolic benefits of GLP-1 receptor agonists across multiple organ systems, finding that the metabolic improvements extend well beyond glycemic control and weight to include markers like uric acid, inflammatory markers, and kidney function indices (PMID 41517401).

---

What This Means If You Have Gout

If you are managing gout and also carrying excess weight, the emerging research suggests that meaningful weight loss may be one of the more powerful tools available to you alongside urate-lowering therapy. GLP-1 medications have produced the largest sustained weight reductions seen in any non-surgical intervention studied to date.

That said, several practical considerations apply.

Gout flares can increase during rapid weight loss. This is a well-documented phenomenon. As fat cells release uric acid during weight loss, serum urate can transiently spike before declining. Some people experience increased flare activity early in a GLP-1 program. If you have gout, this is worth discussing with your provider before starting, so appropriate precautions can be planned.

GLP-1 medications are not approved as gout treatments. The research described here was not conducted to study gout outcomes as a primary endpoint. The uric acid findings are secondary or post-hoc analyses from weight loss trials. GLP-1 medications are studied and prescribed for weight management and metabolic conditions, not for gout specifically.

Medication interactions need review. Some gout medications, including colchicine and NSAIDs, have interactions or tolerability issues that become relevant in the context of GLP-1 therapy and the gastrointestinal side effects it can produce. Your provider and pharmacist should review your full medication list.

Diet remains important. GLP-1 medications reduce appetite and typically shift eating patterns away from the high-purine, high-calorie foods that worsen gout. But specific dietary triggers, organ meats, shellfish, high-fructose corn syrup, and alcohol, can still provoke flares even in a caloric deficit. These remain worth managing directly.

---

The Bigger Picture

Gout is increasingly recognized as a metabolic disease, not just a dietary one. The uric acid-obesity-insulin resistance cluster that drives most cases of gout in adults is the same cluster that drives cardiovascular disease, type 2 diabetes, fatty liver disease, and the other conditions that GLP-1 medications are being studied to address.

This means that for some people, a GLP-1 program may offer benefits that extend across multiple interconnected conditions simultaneously. Weight loss, improved insulin sensitivity, lower blood pressure, better lipid profiles, and now, according to emerging data, lower uric acid levels.

That is not a claim that any single medication treats gout. It is an observation that addressing the shared metabolic root often moves multiple downstream markers in a favorable direction.

---

Talking to Your Provider

If you have gout, hyperuricemia, or both, and you are also managing excess weight, this research is worth bringing to your next appointment. Useful questions to ask include whether your serum urate levels are being monitored, what to expect during a weight loss program with respect to flare risk, whether your current gout regimen should be adjusted before starting a GLP-1 program, and what dietary changes would complement both goals.

Every program at Prescriva starts with a medical evaluation by a licensed healthcare provider, not with a one-size-fits-all prescription. If your history includes gout or elevated uric acid, that becomes part of your clinical picture.

*This is not medical advice. Consult your licensed healthcare provider before making any changes to your medications or treatment plan.*

---

Sources

1. Sattar N, et al. Tirzepatide and change in uric acid and its association with weight reduction: post-hoc analyses of SURMOUNT trials. *Ann Rheum Dis.* 2026. PMID 41198460
2. Moreno-Pérez O, et al. Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: a retrospective real-world analysis. *Semin Arthritis Rheum.* 2025. PMID 40816061
3. Fukui S, et al. Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination. *Arthritis Rheumatol.* 2025. PMID 39400956
4. Soricelli E, et al. Effects of bariatric surgery on hyperuricemia and gout: a systematic review of the literature. *Updates Surg.* 2025. PMID 39520613
5. Lian XF, et al. Study on the correlation between hyperuricemia and components of metabolic syndrome in T2DM in China. *Front Endocrinol (Lausanne).* 2026. PMID 41890181
6. Lixandru N, et al. The Impact of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular-Kidney-Metabolic Health. *J Clin Med.* 2025. PMID 41517401

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.